Pharma firm Natco 
Business

Natco, Mylan caught in patent violation lawsuit

Johnson & Johnson and Momenta Pharmaceuticals lawsuit alleges infringement of two old patents associated with 20mg/ml and 40mg/ml Glatiramer Acetate injection, Natco said in a regulatory filing.

DTNEXT Bureau

NEW DELHI: Homegrown pharma firm Natco on Wednesday said Johnson & Johnson and Momenta Pharmaceuticals have filed a patent infringement lawsuit against the company and its marketing partner Mylan Pharmaceuticals Inc, along with others, in the US.

Johnson & Johnson and Momenta Pharmaceuticals lawsuit alleges infringement of two old patents associated with 20mg/ml and 40mg/ml Glatiramer Acetate injection, Natco said in a regulatory filing. Glatiramer Acetate injection is used to treat relapsing forms of multiple sclerosis in adults.

“This lawsuit has been filed in the Pennsylvania Federal Court. Natco and its marketing partner, Mylan believe this is a meritless suit for a product that has been in the market for more than five years. Mylan and Natco will strongly defend against this suit,” the company said.

Are you in Chennai? Then click here to get our newspaper at your doorstep!

Visit news.dtnext.in to explore our interactive epaper!

Download the DT Next app for more exciting features!

Click here for iOS

Click here for Android

Jallikattu kicks off at new Sooriyur stadium in Tiruchy

Venezuela's acting president adapts to post-Maduro reality and signals a new era of US ties

Rights group alleges killing of 15 minority Hindus in Bangladesh in 45 days

India, Israel strengthen ties in fisheries sector

Red Fort blast: Delhi court allows accused woman doctor to meet advocate in NIA custody